Antibody-drug conjugates, also known as ADC, is a combination of traditional chemotherapy and targeted biological molecule. Recent clinical development brings lots of attention to this particular therapy in oncology filed. In this webinar, we will briefly go over the history and trending of ADC construct, followed by detail discussion of the tools and strategies for antibody discovery, as well as pharmacology assessment of antibody-drug conjugate.
In this talk, you will learn:
Biopharmaceuticals such as antibodies and recombinant proteins represent rapidly expanding categories of drugs offering new therapeutic applications. Achieving maximum production of these molecules is dependent on many factors such as suitable host cells, expression vectors and culture conditions.
In this talk, you will learn:
Dr. Li Chen
Director of Biologics Discovery Dept.,
GenScript ProBio
Dr. Chen Li is the Director of Biologics Discovery Department of GenScript ProBio. After obtaining his doctorate in immunology from the University of Massachusetts School of medicine, he joined GenScript in 2015 and has been responsible for antibody drug discovery platform for the past seven years. He has more than 200 project experience in antibody drug discovery and Engineering innovation optimization, as well as three patents related to biopharmaceutical discovery.
Dr. Lijuan Xu
Senior Scientist of Process
Development dept., GenScript ProBio
Dr. Lijuan Xu received her PhD Degree in Molecular Bacteriology and Infection from University of Copenhagen in 2022. After completing her PhD, she joined ProBio as a Senior Scientist of in Antibody Process Development Department. She is responsible for external technical communication on cell line development and CLD platform and capability improvement.